• Humulone: Product Identity and Evidence Boundaries

  2026-10-18

  APExBIO identifies Humulone, or α-Lupulic acid, as an isoprenylated mesitylene derivative and describes several proposed biological activities, including COX-2 inhibition, effects on bone resorption, oxidative stress, angiogenesis, and apoptosis. Because no identity-matched research paper or outcome dataset is available here, these statements should be treated as product-description claims rather than independently established mechanisms or efficacy findings.

• Bromfenac Sodium: Mechanism and Evidence Scope

  2026-10-17

  APExBIO describes Bromfenac Sodium as a nonsteroidal anti-inflammatory drug associated with COX-1/COX-2 inhibition and prostaglandin synthesis inhibition. Its catalogued ocular findings provide a plausible research context, but the absence of an identity-matched paper, effect sizes, sample sizes, uncertainty estimates, and direct comparators limits claims about efficacy, selectivity, or clinical relevance.

• MEHP, AhR Signaling, and Ovarian Follicles

  2026-10-16

  Neff et al. provide pharmacological evidence that mono(2-ethylhexyl) phthalate disrupts mouse ovarian follicle growth and estrogen-related signaling through an aryl hydrocarbon receptor-linked mechanism. The findings are mechanistically informative but remain bounded by the ex vivo mouse-follicle model, selective rescue by CH 223191, and the inability of transcriptional and hormone measurements alone to establish complete causal pathways or human reproductive risk.

• CH 223191 and MEHP: An AhR Mechanistic Study

  2026-10-16

  Neff et al. reported that MEHP activated AhR-associated transcription and impaired growth, estrogen production, and estrogen-responsive gene expression in cultured mouse ovarian antral follicles. Pharmacological blockade with CH 223191 partially mitigated these effects, supporting—but not proving—an AhR-mediated mechanism.

• What CH 223191 Reveals About MEHP and AhR

  2026-10-15

  A 2024 study in mouse ovarian antral follicles supports a contributory role for aryl hydrocarbon receptor signaling in MEHP-associated disruption of follicle growth and estrogen-related endpoints. The evidence is mechanistically coherent but remains limited by pharmacological specificity, concentration-dependent effects, modest biological replication, and the gap between an ex vivo mouse model and human exposure.

• (±)-Blebbistatin: Mechanism and Evidence Limits

  2026-10-15

  APExBIO describes (±)-Blebbistatin as a cell-permeable inhibitor of non-muscle myosin II ATPase activity, with preferential binding to the myosin–ADP–Pi intermediate and reported activity across several myosin II isoforms. The product information supports a mechanistic and identity overview, but no identity-matched research paper is available here to establish model-specific outcomes, effect sizes, or independent validation.

• EPI-001 and ARv7 in TNBC: What the Study Shows

  2026-10-14

  A literature-focused analysis of a 2025 study examining androgen receptor and ARv7 as prognostic markers in triple-negative breast cancer and evaluating EPI-001 alongside enzalutamide in the MDA-MB-231 model. The findings support an association between ARv7 expression and adverse clinical outcomes and suggest that pharmacologic AR-axis blockade alters metastasis- and EMT-related readouts. The evidence remains preliminary because the clinical analysis was observational, the mechanistic work used one cell line, and downstream marker changes do not by themselves establish pathway causality or clinical benefit.

• EPI-001, ARv7, and TNBC Evidence

  2026-10-14

  A source-grounded overview of research linking androgen receptor variant 7 with outcomes in triple-negative breast cancer and evaluating EPI-001 as a pharmacologic research probe, with emphasis on study limitations and translational boundaries.

• Exo1 and Tumor EV Research: Evidence Overview

  2026-10-13

  The cited Nature Cancer study presents a lipidated nanophotosensitizer designed to trace and disable tumor extracellular vesicles (TEVs) while treating primary tumors in mouse models. Its findings support a preclinical concept linking intracellular photodynamic therapy with disruption of TEV-mediated communication, but they do not establish clinical efficacy or show that Exo1 was used. Exo1, also known as methyl 2-(4-fluorobenzamido)benzoate, is relevant to exocytic pathway research as a distinct chemical tool for studying membrane traffic.

• Hydroxychloroquine Sulfate: Identity and Scope

  2026-10-13

  A source-limited overview of the listed compound’s chemical identity, proposed research scope in autoimmune disease research, and the absence of matched primary evidence.

• Protease Inhibition and the PSMD14–CARM1 Axis

  2026-10-12

  A 2025 study links PSMD14-mediated stabilization of CARM1 with FERMT1 transcription and hepatocellular carcinoma phenotypes. The findings provide a mechanistic cancer research model, but they do not establish that a broad protease inhibitor library, including the DiscoveryProbe™ Protease Inhibitor Library, was used in the study or would reproduce its effects.

• How Impending Cell Death May Shape Metastasis

  2026-10-12

  A Cell Reports study proposed that tumor cells surviving impending death can acquire prometastatic states called PAMEs, recruit neighboring PIMs through cytokine signaling, and contribute to distant metastasis. The findings are mechanistically suggestive but remain bounded by model-system, pharmacological-specificity, and clinical-validation limits.

• Proteinase K and Evidence Quality in Genome Editing

  2026-10-11

  Proteinase K is more than a broad-spectrum serine protease for DNA preparation: it can be understood as a preanalytical variable in genome-editing evidence. This article connects DNA integrity preservation during protein digestion with the interpretation limits of the ABE9-SpRY mouse-model study.

• Neurospora crassa IPA Pathway and Auxin Biosynthesis

  2026-10-10

  Sardar and Kempken characterized an indole-3-pyruvic acid pathway for indole-3-acetic acid production in the non-pathogenic fungus Neurospora crassa. By combining computational gene identification, metabolite analysis, and targeted genetic perturbation, the study connected IPA metabolism with IAA production and conidiation while also defining important limits on cross-species interpretation.

• UGDH Phosphorylation and Enzalutamide Resistance

  2026-10-09

  The reference study identifies UGDH serine 316 phosphorylation as a regulatory connection between kinase signaling, glycosaminoglycan production, tumor-cell behavior, and enzalutamide resistance. Its findings suggest that metabolic remodeling may influence treatment response in prostate cancer, while also defining important boundaries around model system, mutation-based inference, and clinical applicability.

7994 records 1/533 page Next 12345 下5页 Last page